Edwards Lifesciences Corporation
NYSE:EWMedical - Devices
+$0.49 today
- Market cap
- $60.51B
- Beta
- 0.87
- P/E (TTM)
- 46.2
- EPS (TTM)
- $1.89
Volume 3.92M
Average 5.02M
EW Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Edwards Lifesciences CorporationNYSE: EW
Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026
Accounts receivables declines year over year
Q2 FY2026 accounts receivables of $10.2M (cash outflow) fell 59.0% year over year, ahead of the -197.5% change in trailing-twelve-month accounts receivables. Sequentially, it fell 91.3% from the prior quarter. Over 3 fiscal years it compounded at -35.1% a year.
Context
- Accounts receivables amounted to 0.4% of revenue in FY2025, down 1.8 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -59.0% holds above the trailing-twelve-month pace of -197.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (23M) USD
- Year-over-year change
- -119.0%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (23M) | -119.0% |
| FY2024 | 2024-12-31 | 121.2M | +185.8% |
| FY2023 | 2023-12-31 | (141.2M) | -67.9% |
| FY2022 | 2022-12-31 | (84.1M) | +25.2% |
| FY2021 | 2021-12-31 | (112.4M) | — |
Accounts Receivables vs competitors
How EW compares with its peers on the latest reported figures
- EW's LTM Jun 2026 accounts receivables of $82.5M is the 2nd largest of the 6 companies compared; the peer median is $17.77M.
- Its year-over-year change of -197.5% is the lowest of 6, against a peer median of +23.8%.
- Accounts receivables amounts to 1.3% of revenue for EW, versus a peer median of 1.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $370.7M | +242.3% | +23.7% | 3.2% | |
| LTM Jun 2026 | $82.5M | -197.5% | -35.1% | 1.3% | |
| LTM Sep 2026 | $27.33M | +124.1% | +30.6% | 1.8% | |
| LTM Jun 2026 | $17.77M | -172.9% | -34.6% | 1.2% | |
| LTM Mar 2026 | $2.11M | -89.5% | -18.3% | 0.5% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $1.13M | +23.8% | -1.2% | 61.1% |
| Peer median (excluding EW) | $17.77M | +23.8% | -1.2% | 1.8% | |
Competitors are the stored peer set for EW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 1.5B | 1.52B | 1.4B | 4.17B | 1.07B |
| Depreciation & Amortization | 134.8M | 139.6M | 144.9M | 155.2M | 156.6M |
| Deferred Income Tax | (41.4M) | (254.5M) | (272.1M) | (323.4M) | (117.6M) |
| Stock-Based Compensation | 109.3M | 126.8M | 139.4M | 162.3M | 158.1M |
| Change in Working Capital | 145.3M | (421.4M) | (526.3M) | (259.3M) | 154.6M |
| Accounts Receivables | (112.4M) | (84.1M) | (141.2M) | 121.2M | (23M) |
| Inventory | 19M | (213.4M) | (289M) | (256.1M) | 50.7M |
| Accounts Payables | 195.2M | (21.4M) | 146M | 89.5M | 395.1M |
| Other Working Capital | 43.5M | (102.5M) | (242.1M) | (213.9M) | (268.2M) |
| Other Non-Cash Items | (119M) | 105.8M | 7.5M | (3.36B) | 174.1M |
| Operating Cash Flow | 1.73B | 1.22B | 895.8M | 542.3M | 1.6B |
| Capital Expenditures | (329.8M) | (264.8M) | (266.3M) | (252.4M) | (260.2M) |
| Acquisitions (Net) | 329.8M | 0 | (95.2M) | (1.06B) | 0 |
| Purchases of Investments | (1.89B) | (778.9M) | (105.5M) | (945.8M) | (3.14B) |
| Sales of Investments | 529.2M | 1.36B | 715.8M | 857.6M | 2.88B |
| Other Investing Activities | (359.3M) | (63.1M) | (75M) | 3.75B | (195.7M) |
| Investing Cash Flow | (1.72B) | 252.3M | 173.8M | 2.31B | (712.9M) |
| Debt Repayment | (1.8M) | (200K) | (300K) | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 174.1M |
| Common Stock Repurchased | (512.8M) | (1.73B) | (879.6M) | (1.16B) | (893.4M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 158.3M | 142.8M | 168.9M | 176.4M | (237.5M) |
| Financing Cash Flow | (356.3M) | (1.58B) | (711M) | (983M) | (956.8M) |
| Effect of Forex Changes | 13.9M | 19.2M | 16.8M | 38.6M | (44.8M) |
| Net Change in Cash | (332.8M) | (94.8M) | 375.4M | 1.91B | (119.3M) |
| Free Cash Flow | 1.4B | 953.4M | 629.5M | 289.9M | 1.34B |
Edwards Lifesciences Corporation
NYSE:EW
Intrinsic Alpha fair value
Locked
Current Price
$105.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.